Extrawell Pharmaceutical Holdings Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Extrawell Pharmaceutical Holdings hat ein Gesamteigenkapital von HK$1.1B und eine Gesamtverschuldung von HK$117.1M, was einen Verschuldungsgrad von 10.5% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen HK$1.3B bzw. HK$174.6M.

Wichtige Informationen

10.5%

Verhältnis von Schulden zu Eigenkapital

HK$117.12m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	HK$95.01m
Eigenkapital	HK$1.11b
Gesamtverbindlichkeiten	HK$174.58m
Gesamtvermögen	HK$1.29b

Jüngste Berichte zur Finanzlage

Recent updates

Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

Mar 18

Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

Dec 01

We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Aug 04

Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

Mar 15

Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

Aug 20

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 858Die kurzfristigen Aktiva des Unternehmens (HK$177.4M) übersteigen seine kurzfristigen Passiva (HK$51.4M).

Langfristige Verbindlichkeiten: 858Die kurzfristigen Vermögenswerte des Unternehmens (HK$177.4M) übersteigen seine langfristigen Verbindlichkeiten (HK$123.2M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 858Die Nettoverschuldung im Verhältnis zum Eigenkapital (2%) wird als zufriedenstellend angesehen.

Schulden abbauen: 858Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 4.7% auf 10.5% gestiegen.

Schuldendeckung: 858Der operative Cashflow des Unternehmens ist negativ, so dass die Schulden nicht ausreichend gedeckt sind.

Zinsdeckung: Unzureichende Daten, um zu bestimmen, ob die Zinszahlungen von 858 für seine Schulden durch das EBIT gut gedeckt sind.

Extrawell Pharmaceutical Holdings Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

Recent updates

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2025 Results on Nov 29, 2024

New major risk - Share price stability

New major risk - Market cap size

Full year 2024 earnings released: HK$0.068 loss per share (vs HK$0.054 profit in FY 2023)

Extrawell Pharmaceutical Holdings Limited, Annual General Meeting, Aug 23, 2024

Full year 2024 earnings released: HK$0.068 loss per share (vs HK$0.054 profit in FY 2023)

Extrawell Pharmaceutical Holdings Limited to Report Fiscal Year 2024 Results on Jun 28, 2024

Extrawell Pharmaceutical Holdings Limited Announces Board and Committee Changes

Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

New major risk - Share price stability

New major risk - Market cap size

First half 2024 earnings released: HK$0.099 loss per share (vs HK$0.019 profit in 1H 2023)

Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

New major risk - Revenue and earnings growth

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Nov 29, 2023

New minor risk - Share price stability

Full year 2023 earnings released: EPS: HK$0.054 (vs HK$0.055 in FY 2022)

Extrawell Pharmaceutical Holdings Limited, Annual General Meeting, Aug 25, 2023

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: HK$0.054 (vs HK$0.055 in FY 2022)

New minor risk - Financial data availability

Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023

Extrawell Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Jun 29, 2023

Extrawell Pharmaceutical Holdings Limited Announces Demise of Mr. Xue Jing Lun, Independent Non-Executive Director, and A Member of Each of the Audit Committee, Remuneration Committee and Nomination Committee

First half 2023 earnings released: EPS: HK$0.019 (vs HK$0.037 in 1H 2022)

Extrawell Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 September 2022

Less than half of directors are independent

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Nov 29, 2022

Extrawell Pharmaceutical Holdings Limited Announces Management Changes

We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Full year 2022 earnings released: EPS: HK$0.055 (vs HK$0.051 loss in FY 2021)

Extrawell Pharmaceutical Holdings Limited, Annual General Meeting, Aug 30, 2022

Full year 2022 earnings released

Extrawell Pharmaceutical Holdings Limited Provides Earnings Guidance for the Year Ended March 31, 2022

Extrawell Pharmaceutical Holdings Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

Full year 2021 earnings released: HK$0.051 loss per share (vs HK$0.035 profit in FY 2020)

Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended March 31, 2021

First half 2021 earnings released: EPS HK$0.031

First half 2021 earnings released: EPS HK$0.031

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2021 Results on Nov 27, 2020

Mao Yumin completed the acquisition of 19.14% stake in Extrawell Pharmaceutical Holdings Limited (SEHK:858) from Innovative Pharmaceutical Biotech Limited (SEHK:399).

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen